Difficulty: Medium
Average Score: 89%
Testbank
In the treatment of coronary artery disease (CAD), medications are often ordered to control blood pressure in the client. Which of the following is a primary purpose of using beta-adrenergic blockers in the nursing management of CAD?
Correct answer
B
Rationale
Beta-adrenergic blockers are primarily used in the nursing management of CAD to decrease the workload of the heart.
These medications reduce heart rate and contractility, leading to decreased myocardial oxygen demand and lower blood pressure. This is particularly important in CAD, as it helps manage symptoms and prevent further cardiac events by minimizing strain on the heart.
A: To dilate coronary arteries
Beta-adrenergic blockers do not primarily function to dilate coronary arteries; their main role involves reducing heart rate and contractility rather than directly affecting vascular dilation.
C: To decrease homocysteine levels
Beta-adrenergic blockers do not have a direct effect on homocysteine levels, which are more closely related to metabolic processes rather than the pharmacological actions of these medications in CAD management.
D: To prevent angiotensin II conversion
Preventing angiotensin II conversion is a function of ACE inhibitors, not beta-adrenergic blockers; thus, this option does not align with the primary purpose of beta-blockers in treating CAD.
These medications reduce heart rate and contractility, leading to decreased myocardial oxygen demand and lower blood pressure. This is particularly important in CAD, as it helps manage symptoms and prevent further cardiac events by minimizing strain on the heart.
A: To dilate coronary arteries
Beta-adrenergic blockers do not primarily function to dilate coronary arteries; their main role involves reducing heart rate and contractility rather than directly affecting vascular dilation.
C: To decrease homocysteine levels
Beta-adrenergic blockers do not have a direct effect on homocysteine levels, which are more closely related to metabolic processes rather than the pharmacological actions of these medications in CAD management.
D: To prevent angiotensin II conversion
Preventing angiotensin II conversion is a function of ACE inhibitors, not beta-adrenergic blockers; thus, this option does not align with the primary purpose of beta-blockers in treating CAD.